Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications.
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an annual incidence of 1-2% of gastrointestinal (GI) complications, which may be fatal in some cases. Low-dose aspirin is also associated with an increased risk of upper GI bleeding, but the increase is about three times lower than that found with common NSAIDs. Misoprostol (600-800 microg/day) reduces the incidence of complications in non-aspirin NSAID users. Co-therapy with antisecretory drugs (proton pump inhibitors, PPIs) also reduces the risk of GI bleeding in high-risk patients taking NSAIDs and/or low-dose aspirin. Another way of reducing the incidence of GI complications is to use the highly selective cyclo-oxygenase 2 (COX-2) inhibitors. The GI safety of nitric oxide NSAIDs (NO-NSAIDs) has been demonstrated extensively in experimental conditions and preliminary clinical studies. Epidemiological studies have also shown that nitric oxide donor drugs reduce the risk of upper GI bleeding, which might be important in patients receiving low-dose aspirin.
Lanas
A
A
Service of Gastroenterology, University Hospital, Zaragoza, Spain.
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011322:Primary Prevention / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin